Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126

類似資料

• Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging
  著者:: Robinson, S P, 等
  出版事項: (2003)
• Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
  著者:: Li, J, 等
  出版事項: (2014)
• Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts
  著者:: Bozec, A, 等
  出版事項: (2007)
• Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
  著者:: Martinelli, M, 等
  出版事項: (2007)
• The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues
  著者:: Gaballah, K, 等
  出版事項: (2009)